JAMA Internal Medicine
APRIL 21, 2024
In this study, Dave et al harness national Veterans Health Administration (VHA) clinical data to examine the association between initiation of a new antihypertensive agent with the incidence of fall-related fractures in residents at VHA nursing homes, or community living centers. fold greater risk of serious falls (HR, 1.80 [95% CI, 1.52-2.13])
The Pharma Data
MARCH 25, 2021
months with letrozole alone (HR 0.58: 95% CI, 0.49 months among patients in the letrozole group (HR 0.66: 95% CI, 0.53 This real-world cohort includes more than 1,400 women with HR+, HER2- mBC with any extent of visceral disease. months with IBRANCE plus letrozole versus 11.9 to 0.82; P=0.0002). in the IBRANCE group and 68.0%
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Triage Cancer
APRIL 27, 2021
FREE continuing education credits/contact hours for social workers and nurses, 7 FREE continuing education credits for patient advocates, and 6 FREE PDCs for HR professionals. Continuing Education for Professionals. This event also offers 6.5 What have past attendees said about our Conferences?
Pfizer
AUGUST 15, 2022
PAXLOVID may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs in the therapeutic class to which PAXLOVID belongs (i.e., PAXLOVID is not authorized for use for longer than 5 consecutive days.
The Pharma Data
FEBRUARY 8, 2021
IBRANCE is indicated for the treatment of adult patients with HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women or in men; or with fulvestrant in patients with disease progression following endocrine therapy. 2,3 In the U.S.,
Pfizer
JANUARY 27, 2023
telehealth, in-person visit) with a physician, advanced practice registered nurse, or physician assistant licensed or authorized under state law to prescribe drugs, if any of the following apply: Sufficient information is not available to assess renal and hepatic function.
The Pharma Data
JUNE 18, 2021
months; hazard ratio [HR] 0.33 [95% CI 0.25-0.45]); with chlorambucil in combination with obinutuzumab (Obi-Clb; HR 0.85, 95% CI [0.54-1.35]; Advise nursing women to discontinue breastfeeding during treatment. After a median follow-up of more than four years (52.4 0.45]); results are descriptive. with Ven-Obi versus 83.1%
Expert insights. Personalized for you.
40 
Let's personalize your content